Emergent BioSolutions | EBS - Cash And Equivalent

Stock Price
10.93
Daily Change
-0.06 -0.55%
Monthly
-4.96%
Yearly
41.76%
Q1 Forecast
10.65

Emergent BioSolutions reported $111.7M in Cash and Equivalent for its fiscal quarter ending in December of 2023.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 847.02M 85.02M Sep/2025
Akebia Therapeutics USD 166.44M 29.14M Sep/2025
ALKERMES USD 616.45M 95.25M Sep/2025
Alnylam Pharmaceuticals USD 1.66B 167M Dec/2025
Amarin USD 122.8M 25.08M Sep/2025
ANI Pharmaceuticals USD 262.61M 44.81M Sep/2025
BioMarin Pharmaceutical USD 1.25B 36.29M Sep/2025
Coherus Biosciences USD 103.35M 113.54M Sep/2025
Emergent BioSolutions USD 111.7M 23.9M Dec/2023
Exact Sciences USD 956M 166.96M Dec/2025
Exelixis USD 482.49M 106.19M Dec/2025
Glaxosmithkline GBP 3.3B 303M Sep/2025
Heron Therapeutics USD 43.07M 26.55M Sep/2025
Ionis Pharmaceuticals USD 2.24B 1.94B Sep/2025
Ironwood Pharmaceuticals USD 140.41M 47.56M Sep/2025
Lexicon Pharmaceuticals USD 21.36M 41.52M Jun/2025
Lonza CHF 1.11B 286M Dec/2024
Merck USD 18.17B 10.16B Sep/2025
Moderna USD 2.6B 1.46B Dec/2025
Myriad Genetics USD 145.4M 71M Sep/2025
Nektar Therapeutics USD 41.03M 1.96M Sep/2025
Neurocrine Biosciences USD 713M 372.8M Dec/2025
Pacira USD 147.59M 152.89M Sep/2025
Pfizer USD 1.34B 295M Sep/2025
PTC Therapeutics USD 984.65M 312.03M Dec/2025
Sanofi EUR 7.66B 1.25B Dec/2025
Sarepta Therapeutics USD 613.08M 102.48M Sep/2025
United Therapeutics USD 1.34B 253M Sep/2025
Vanda Pharmaceuticals USD 84.85M 14.83M Dec/2025
Xoma USD 143.9M 7.68M Jun/2024